Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Interlaboratory Studies using the NISTmAb to Advance Biopharmaceutical Structural Analytics

Published

Author(s)

Katharina Yandrofski, Trina Mouchahoir, M. Lorna De Leoz, David L. Duewer, Jeffrey W. Hudgens, Kyle Anderson, Luke Arbogast, Frank Delaglio, Robert Brinson, John Marino, Karen W. Phinney, Michael J. Tarlov, John E. Schiel

Abstract

Biopharmaceuticals such as monoclonal antibodies are required to be rigorously characterized using a wide range of analytical methods. Various material properties must be characterized and well controlled to assure that clinically relevant features and critical quality attributes are maintained. A thorough understanding of the performance metrics of an analytical method, particularly emerging methods designed to address measurement gaps, using an industrially relevant test system is required to assure that applied methods are implemented in a manner conducive to their intended use in assuring drug safety, stability, and functional activity. To this end, a series of interlaboratory studies have been conducted using NISTmAb, a biopharmaceutical-representative and publicly available test material, to report on state-of-the-art method performance, harmonize best practices, and inform on potential gaps in the analytical measurement infrastructure. Reported here is a summary of the study designs, results and future perspectives revealed from these interlaboratory studies which focused on primary structure, post-translational modifications, and higher order structure measurements currently employed during biopharmaceutical development.
Citation
Frontiers in Molecular Biosciences

Keywords

Monoclonal Antibody, Biopharmaceutical, NISTmAb, Therapeutic Protein, Interlaboratory Study

Citation

Yandrofski, K. , Mouchahoir, T. , De Leoz, M. , Duewer, D. , Hudgens, J. , Anderson, K. , Arbogast, L. , Delaglio, F. , Brinson, R. , Marino, J. , Phinney, K. , Tarlov, M. and Schiel, J. (2022), Interlaboratory Studies using the NISTmAb to Advance Biopharmaceutical Structural Analytics, Frontiers in Molecular Biosciences, [online], https://doi.org/10.3389/fmolb.2022.876780, https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=934084 (Accessed February 8, 2023)
Created May 5, 2022, Updated November 29, 2022